Gyeonggi-do, South Korea

Hyoun Sook Kim

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Hyoun Sook Kim

Introduction: Hyoun Sook Kim, an accomplished inventor based in Gyeonggi-do, South Korea, has made significant contributions to the field of pharmaceuticals, specifically aimed at addressing critical health issues. With one notable patent to his name, Kim is recognized for his innovative approach in developing therapeutic solutions.

Latest Patents: Hyoun Sook Kim's patent revolves around an inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL). This invention not only serves as an effective anticancer agent capable of overcoming resistance to EGFR-targeting anticancer therapies but also shows promise in the treatment of hyperlipidemia. The dual functionality of this compound marks it as a significant breakthrough in medical research and treatment methodologies.

Career Highlights: Throughout his career, Kim has collaborated with esteemed organizations such as the Seoul National University R&DB Foundation and the Korea Research Institute of Chemical Technology. His work in these institutions highlights his commitment to advancing scientific understanding and practical applications of innovative medical treatments.

Collaborations: Hyoun Sook Kim has worked alongside prominent professionals including Bong-Jin Lee and Kyu-Yeon Lee. These collaborations have been essential in driving forward research initiatives and developing cutting-edge solutions in the pharmaceutical sector.

Conclusion: In summary, Hyoun Sook Kim stands out as a pioneering inventor whose work significantly impacts the fields of oncology and lipid management. His innovative patent illustrates a dedicated effort to enhance therapeutic options for patients, showcasing his invaluable contribution to medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…